Telix Pharmaceuticals Ltd ADR (TLX)
Telix Pharmaceuticals Ltd ADR (NASDAQ: TLX) is a depositary receipt representing common stock of Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals. The company operates across three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its pipeline includes TLX591, a lutetium-labeled radio antibody-drug conjugate in Phase 3 development for advanced prostate cancer, along with candidates such as TLX250 for metastatic kidney cancer, TLX101 for glioblastoma, TLX66 for bone marrow conditioning, and several other programs targeting oncology and imaging applications. Telix also markets Illuccix and Gozellix for prostate cancer, and is advancing diagnostic assets including BiPASS, AlFluor, TLX250-Px, and TLX101-Px. The company has operations in Australia, Europe, North America, the United Kingdom, and other international markets, and maintains a strategic collaboration with University Hospital Essen.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TLX
|
$12.20
|
2.1% Upside
|
Fair
|
$19.94
|
66.8% Upside
|
Bargain
|
Good
|
0.0%
|
October 22, 2026
|
121.2x
|
8.3x
|
4.6x
|
4.06 B
|
4.357 B
|
12.0%
|
80.5%
|
5.9
|
-135.8%
|
